stockportfolio.pro
Stocks / ABT vs AZN
ABT vs AZN
Abbott Laboratories and AstraZeneca PLC side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Abbott Laboratories (ABT) | AstraZeneca PLC (AZN) | |
|---|---|---|
| Market cap | $154.4B | $281.1B |
| Revenue (latest FY) | $44.33B | $58.74B |
| Net income (latest FY) | $6.52B | $10.22B |
| Revenue growth (5y CAGR) | 5.1% | 9.8% |
| Net margin | 14.7% | 17.4% |
| Return on equity | 12.5% | 21.0% |
| P/E ratio | 24.7 | 27.3 |
| Dividend yield | 2.9% | 1.8% |
| Profitable years (of last 10) | 10 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABT — free Open AZN — freeFrequently asked questions
Which is bigger, ABT or AZN?
AstraZeneca PLC is larger by market capitalization — $281.1B versus $154.4B.
Which grows faster, ABT or AZN?
Over the last five fiscal years, AstraZeneca PLC grew revenue faster — 9.8%/yr versus 5.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.